FY2025 Q2 Earnings Announcement
Committed to Growth & Shareholder Returns

from the beginning

FY2025 Q2 Earnings Announcement Committed to Growth & Shareholder Returns

Important Notice

AGENDA

1. Opening Remarks

Business Fundamentals Tracking as Planned During a Pivotal Year for the Pipeline

2. Financial Highlights

FY2025 H1: Core Business Performance Tracking as Planned; Expecting Better Growth Outlook for the Full-year

Growth & Launch Products +5.3% at CER in H1; Higher Growth Rate Anticipated in H2

FY2025 H1 Revenue: Impacted by VYVANSE Generics as Expected; Projecting More Favorable Year-on-Year Growth Dynamics in H2

Driving OPEX Savings Through Efficiency Improvements

FY2025 H1 Core Operating Profit: Operational Efficiencies Deliver Year-on-Year Reduction in R&D and SG&A Expenses

FY2025 H1 Reported Operating Profit: Includes Impairment Related to Cell Therapy Discontinuation

FY2025 Management Guidance Updated due to Transactional FX; Reported Profit Forecasts Reflect Non-tax Deductible Impairment in H1

FY2025 Core Operating Profit Forecast: OPEX Savings Fully Mitigate Change in Product Mix; Incremental Headwind from Transactional FX

Business Fundamentals Tracking as Planned During a Pivotal Year for the Pipeline

3. Pipeline Update

FY2025 a Pivotal Year as We Prepare for Late-Stage Pipeline Launches

Towards a New Standard: Oveporexton 2/2mg Demonstrated Normalized Daytime and Nighttime Symptoms in Majority of NT1 Patients

Mezagitamab: First IgAN Therapy with Durable eGFR 18 months After Last Dose

Delivering Our Late-Stage Programs that have the Potential to Transform Lives and Generate Significant Value

4. Partnership with Innovent Biologics

A Strategic Oncology Partnership Representing a Significant Future Growth Opportunity for Takeda

Global Partnership Significantly Expands our Late-stage Oncology Pipeline

Augments Portfolio with Next Generation Programs that Target Solid Tumors in Areas of High Unmet Need and are a Strong Fit with our Oncology Strategy

IBI363: Potential First-in-class PD-1/IL-2α Biased Bispecific Antibody Fusion Protein

Against the Backdrop of a Competitive Landscape IBI363 has Demonstrated Encouraging Data Across Multiple Solid Tumor Types

An Ambitious Initial Clinical Development Program to Establish IBI363 as a Backbone IO Therapy with Extensive Expansion Opportunities

IBI343: Potentially Best-in-Class CLDN18.2 Targeted Therapy Addressing Unmet Need in Pancreatic and Gastric Cancer

IBI343: Differentiated Profile with Encouraging Data that Address Critical Unmet Need

Clinical Development Program for IBI343 to Address High Unmet Need in Pancreatic and Gastric Cancers

IBI3001: Potential First-in-class Bispecific EGFR/B7H3 ADC

Collaboration Adds Investigational Medicines in Four of the Most Common and Difficult to Treat Cancers Worldwide with Extensive LCM Opportunities

IBI363 Potential Addressable Market Opportunity $40B+ Within Initial Indications

IBI343 Potential Addressable Market Opportunity ~$8B

A Strategic Oncology Partnership with Potential to Deliver Significant Value for Patients and Takeda

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

• Q&A SESSION8

• Q&A SESSION9

• Q&A SESSION10

APPENDIX